Author

Lynne Merchant

BOTH SINGLE AND MULTIPLE SWITCHING BETWEEN INFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE IN IBD: REAL WORLD OUTCOMES FROM THE EDINBURGH IBD UNIT
BOTH SINGLE AND MULTIPLE SWITCHING BETWEEN INFLIXIMAB BIOSIMILARS CAN BE SAFE AND EFFECTIVE IN IBD: REAL WORLD OUTCOMES FROM THE EDINBURGH IBD UNIT

Lynne Merchant  et al.

LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD
LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD

Lynne Merchant  et al.

Item 1 - 2 / 2
1